Pittcon

Press Release

Dr. Schena to chair microarray symposium

Sunnyvale, CA, January 27, 2003 – On January 22nd the Coalesce Corporation, on behalf of the Pittsburgh Conference Committee, announced that it had chosen TeleChem’s Visiting Scholar Dr. Mark Schena to chair the inaugural Microarray Symposium at PITTCON 2003. The event will be held on March 9-14 at the Orange County Convention Center in Orlando Florida.

The Pittsburgh Conference or “PITTCON” was founded in 1950 to bring together researchers from basic and applied scientists to solve important scientific problems. Using science education as the underlying charter, PITTCON has grown into the world’s largest scientific conference in the United States. This year’s conference in Orlando will feature more than 1,100 vendors and 25,000 attendees. The Microarray Symposium will be the first event of its kind at PITTCON 2003.

“When the meeting organizers contacted me, I was fully booked”, said Dr. Schena. “But the size, scope and renown of the show were too exciting to pass up. It is a great privilege to be asked to Chair the inaugural Microarray Symposium at this year’s meeting.”

About TeleChem International, Inc.
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.

Media Contact
Paul Haje
Director of Public Relations
408-744-1331
Email: paul@ArrayIt.com